Pharmacologic management of acutely agitated pediatric patients

Pediatric Drugs

Volumn 13, Issue 1, 2011, Pages 1-10

  Sonnier, Loretta ^a   Barzman, Drew ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUTYROPHENONE DERIVATIVE; DIAZEPAM; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; HALOPERIDOL; HYDROXYZINE; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; PROPRANOLOL; RISPERIDONE; ZIPRASIDONE;

ACUTE AGITATION; AKATHISIA; ANXIETY DISORDER; APPETITE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; CONDUCT DISORDER; CONSTIPATION; DELIRIUM; DIZZINESS; DRUG SAFETY; DRY SKIN; DYSLIPIDEMIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLUSHING; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INSOMNIA; MENTAL DEFICIENCY; METABOLIC SYNDROME X; MYDRIASIS; NEUROLEPTIC MALIGNANT SYNDROME; PARADOXICAL DRUG REACTION; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; TACHYCARDIA; TORSADE DES POINTES; TREATMENT INDICATION; TREATMENT OUTCOME; URINE RETENTION; XEROSTOMIA;

ACUTE DISEASE; ADOLESCENT; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; BENZODIAZEPINES; CHILD; HISTAMINE ANTAGONISTS; HUMANS; PSYCHOMOTOR AGITATION;

EID: 78650343765     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11538550-000000000-00000     Document Type: Review

References (72)

1. Bogner JA, Corrigan JD, Bode RK, et al. Rating scale analysis of the Agitated Behavior Scale. J Head Trauma Rehabil 2000 Feb; 15 (1): 656-69
2. Bogner J. The agitated behavior scale. The Center for Outcome Measurement in Brain Injury (COMBI), 2000 [online]. Available from URL: http://tbims. org/combi/abs/index.html [Accessed 2010 Oct 21]
3. Silva RR. Psychopharmacology news. J Child Adolesc Psychopharmacol 2007 Dec; 17 (6): 871-2
4. Hilt RJ, Woodward TA. Agitation treatment for pediatric emergency patients. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 132-8
5. Petti TA, Stigler KA, Gardner-Haycox J, et al. Perceptions of P.R.N. psychotropic medications by hospitalized child and adolescent recipients. J Am Acad Child Adolesc Psychiatry 2003 Apr; 42 (4): 434-41
6. Masters KJ, Bellonci C, Bernet W, et al. Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. JAmAcad Child Adolesc Psychiatry 2002 Feb; 41 (2 Suppl.): 4-25S
7. Duverger P, Picherot G, Champion G, et al. Turbulence in emergency ward: agitation of children and adolescents. Arch Pediatr 2006 Jun; 13 (6): 819-22
8. Cummings MR, Miller BD. Pharmacologic management of behavioral instability in medically ill pediatric patients. Curr Opin Pediatr 2004 Oct; 16 (5): 516-22
9. Kratochvil CJ, Findling RL, McDougle CJ, et al. Pharmacological management of agitation and aggression in an adolescent with autism. J Am Acad Child Adolesc Psychiatry 2005 Aug; 44 (8): 829-32
10. Jensen PS, Youngstrom EA, Steiner H, et al. Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry 2007 Mar; 46 (3): 309-22
11. Barzman DHD, DelBello MP, Adler CM, et al. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occuring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol 2006; 16 (6): 665-70
12. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression: I. A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002 Mar; 41 (3): 253-61
13. Schur SB, Sikich L, Findling RL, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): part I.Areview. JAmAcad Child Adolesc Psychiatry 2003 Feb; 42 (2): 132-44 (Pubitemid 39610593)
14. Pappadopulos E, Macintyre IIJC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): part II. J Am Acad Child Adolesc Psychiatry 2003 Feb; 42 (2): 145-61 (Pubitemid 39610594)
15. Dolan MA, Mace SE. Pediatric mental health emergencies in the emergency medical services system. Pediatrics 2006 Oct; 118 (4): 1764-7
16. Schieveld JN, van der Valk JA, Smeets I. Diagnostic considerations regarding pediatric delirium: a review and a proposal for an algorithm for pediatric intensive care units. Intensive Care Med 2009; 35: 1843-9
17. Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65 (9): 1207-22
18. Zimbroff DL. Pharmacological control of acute agitation: focus on intramuscular preparations. CNS Drugs 2008; 22 (3): 199-212
19. Martin A, Volkmar FR, editors. Lewis child and adolescent psychiatry: a comprehensive textbook. 4th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2007
20. Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006 Jan; 12 (1): 30-40
21. Dulcan M, editor. Dulcans textbook of child and adolescent psychiatry. New York: American Psychiatric Publishing, 2009
22. Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004 Mar; 65 (3): 386-94
23. Pediatric Lexi-Drugs online . Hudson (OH): Lexi-Comp, Inc., 2010 [online]. Available from URL: www.lexi.com [Accessed 2010 16 Nov]
24. Barzman DH, Delbello MP. Clinically useful approaches for the atypical antipsychotics (second generation antipsychotics) in pediatric psychotic disorders. Child Adolesc Psychopharmacol News 2004; 9 (6): 6-9
25. Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol 2006 Dec; 16 (6): 671-7
26. Barzman DH, DelBello MP, Forrester JJ, et al. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed. J Child Adolesc Psychopharmacol 2007 Aug; 17 (4): 503-9
27. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003 Jan; 157 (1): 17-25
28. Pappadopulos E, Jensen PS, Schur SB, et al. "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 2002; 28 (1): 111-21
29. Green W. Child and adolescent psychopharmacology. 4th ed. New York: Lippincott Williams and Wilkins, 2007
30. dosReis S, Barnett S, Love RC, et al. A guide for managing acute aggressive behavior of youths in residential and inpatient treatment facilities. Psychiatr Serv 2003 Oct; 54 (10): 1357-63
31. de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr 2008 Feb; 13 (2): 133-5
32. Sadock BJ, Sadock VA. Kaplan and Sadocks synopsis of psychiatry: behavioral sciences, clinical psychiatry. 9th ed. Philadelphia (PA): Lippincott, Williams and Wilkins, 2003
33. Dorfman DH, Kastner B. The use of restraint for pediatric psychiatric patients in emergency departments. Pediatr Emerg Care 2004 Mar; 20 (3): 151-6
34. Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series: treatment of behavioral emergencies 2005. J Psychiatr Pract 2005 Nov; 11 Suppl. 1: 5-108; quiz 110-2
35. Sorrentino A. Chemical restraints for the agitated, violent, or psychotic pediatric patient in the emergency department: controversies and recommendations. Curr Opin Pediatr 2004 Apr; 16 (2): 201-5
36. Stahl S. Essential psychopharmacology: the prescribers guide, revised and updated edition. New York: Cambridge University Press, 2006
37. Gutierrez MA, Roper JM, Hahn P. Paradoxical reactions to benzodiazepines. Am J Nurs 2001 Jul; 101 (7): 34-9; quiz 39-40
38. Paton C. Benzodiazepines and disinhibition: a review. Psychiatr Bull 2002; 26: 460-2
39. Dorfman D. The use of physical and chemical restraints in the pediatric emergency department. Pediatr Emerg Care 2000 Oct; 16 (5): 355-60
40. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004 Nov; 114 (5): 634-41
41. Ty EB, Rothner AD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 2001 Mar; 16 (3): 157-63
42. OlfsonM, Blanco C, Liu L.National trends in outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006 Jun; 63 (6): 679-85
43. Joshi PT, Hamel L, Joshi AR, et al. Use of droperidol in hospitalized children. J Am Acad Child Adolesc Psychiatry 1998 Feb; 37 (2): 228-30
44. Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003 Jun; 42 (6): 642-50
45. Lukens TW, Wolf SJ, Edlow JA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med 2006 Jan; 47 (1): 79-99
46. Stuth EA, Stucke AG, Cava JR, et al. Droperidol for perioperative sedation causes a transient prolongation of the QTc time in children under volatile anesthesia. Paediatr Anaesth 2004 Oct; 14 (10): 831-7
47. Cheng-Shannon J, McGough JJ, Pataki C, et al. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004 Fall; 14 (3): 372-94
48. Antia SX, Sholevar EH, Baron DA. Overdoses and ingestions of secondgeneration antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 2005 Dec; 15 (6): 970-85
49. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47 (1): 9-20
50. Munarriz R, Bennett L, Goldstein I. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002 Dec 5; 347 (23): 1890-1; author reply 1891
51. Hatta K, Kawabata T, Yoshida K, et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry 2008 Jul-Aug; 30 (4): 367-71
52. Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practive with ziprasidone IM: update after 2 years of experience. CNS Spectr 2005 Sep; 10 (9): 1-15
53. Hazaray E, Ehret J, Posey DJ, et al. Intramuscular ziprasidone for acute agitation in adolescents. J Child Adolesc Psychopharmacol 2004 Fall; 14 (3): 464-70
54. Staller JA. Intramuscular ziprasidone in youth: a retrospective chart review. J Child Adolesc Psychopharmacol 2004 Winter; 14 (4): 590-2
55. Scott LK, Green R, McCarthy PJ, et al. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. J Neurosurg Pediatr 2009 Jun; 3 (6): 484-7
56. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (ziprasidone HCL), 19 Jul 2000: 78 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf [Accessed 2010 Oct 21]
57. Geodon: US full prescribing information [online]. Available from URL: www.geodon.com [Accessed 2010 Nov 17]
58. Glassman AH, Bigger Jr JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001 Nov; 158 (11): 1774-82
59. Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 2005; 19 (2): 147-64
60. Zyprexa full prescribing information. Eli Lilly and Company, 2009
61. Wilhelm S, Schacht A, Wagner T. Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: results of an observational trial. BMC Psychiatry 2008; 8: 61
62. Reeves RR, Torres RA. Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. SouthMed J 2003 Jul; 96 (7): 699-701
63. Abilify: US full prescribing information [online]. Available from URL: www.abilify.com [Accessed 2010 Nov]
64. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007 Dec; 68 (12): 1876-85
65. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, doubleblind, placebo-controlled trial. J Clin Psychiatry 2007 Jan; 68 (1): 111-9
66. Barzman DH, DelBello MP, Kowatch RA, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacology 2004; 14 (4): 593-600
67. Shaw RJDD. Clinical manual of pediatric psychosomatic medicine. Arlington (VA): American Psychiatric Publishing, 2006
68. Correll CU, Penzner JB, Parikh UH. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adoloescents. Child Adolesc Psychiatr Clin North Am 2006 Jan; 15 (1): 177-206
69. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003 Jul; 39 (7): 551-7
70. Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol 2009 Aug; 19 (4): 415-22
71. Silva RR, Munoz DM, Alpert M, et al. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999 Feb; 38 (2): 187-94
72. Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999 Feb 23; 99 (7): 979-82